DCAF退:

Qi Miao1, Vilas D Kadam1, Ayan Mukherjee1

  • 1Center for Drug Discovery, Department of Pathology & Immunology, and Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States.

PubMed
概括

向蛋白质降解 (TPD) 使用新型E3链酶来克服药物耐药性. 这项研究探讨释放CRL4 ((DCAF) 连接酶,以开发新的降解药物,扩大治疗选择.